Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sunil Sabharwal is active.

Publication


Featured researches published by Sunil Sabharwal.


Journal of Spinal Cord Medicine | 2007

Health care costs for patients with chronic spinal cord injury in the Veterans Health Administration.

Dustin D. French; Robert R. Campbell; Sunil Sabharwal; Audrey Nelson; Polly Palacios; Deborah Gavin-Dreschnack

Abstract Background/Objective: Recurring annual costs of caring for patients with chronic spinal cord injury (SCI) is a large economic burden on health care systems, but information on costs of SCI care beyond the acute and initial postacute phase is sparse. The objective of this study was to establish a frame of reference and estimate of the annual direct medical costs associated with health care for a sample of patients with chronic SCI (ie, >2 years after injury). Methods: Patients were recruited from 3 Veterans Health Administration (VHA) SCI facilities; baseline patient information was cross-referenced to the Decision Support System (DSS) National Data Extracts (NDE) to obtain patient-specific health care costs in VHA. Descriptive statistical analysis of annual DSS-NDE cost of patients with SCI (N = 675) for fiscal year (FY) 2005 by level and completeness of injury was conducted. Results: Total (inpatient and outpatient) annual (FY 2005) direct medical costs for 675 patients with SCI exceeded


The Journal of Neuroscience | 2005

Respiratory Abnormalities Resulting from Midcervical Spinal Cord Injury and their Reversal by Serotonin 1A Agonists in Conscious Rats

Howard Choi; Wei-Lee Liao; Kimberly M. Newton; Renna C. Onario; Allyson M. King; Federico C. Desilets; Eric J. Woodard; Marc E. Eichler; Walter R. Frontera; Sunil Sabharwal; Yang D. Teng

14.47 million or


Regenerative Medicine | 2006

Physical activity-mediated functional recovery after spinal cord injury: potential roles of neural stem cells

Yang D. Teng; Wei-Lee Liao; Howard Choi; Deniz Konya; Sunil Sabharwal; Robert Langer; Richard L. Sidman; Evan Y. Snyder; Walter R. Frontera

21,450 per patient. Average annual total costs varied from


Neuroscience Letters | 2006

Therapeutic effects of clenbuterol in a murine model of amyotrophic lateral sclerosis.

Yang D. Teng; Howard Choi; Wenzheng Huang; Renna C. Onario; Walter R. Frontera; Evan Y. Snyder; Sunil Sabharwal

28,334 for cervical complete SCI to


Pm&r | 2009

VA-Based Survey of Osteoporosis Management in Spinal Cord Injury

Leslie R. Morse; Lora Giangregorio; Ricardo A. Battaglino; Robert Holland; B. Catharine Craven; Kelly Stolzmann; Antonio A. Lazzari; Sunil Sabharwal; Eric Garshick

16,792 for thoracic incomplete SCI. Two hundred thirty-three of the 675 patients with SCI who were hospitalized over the study period accounted for a total of 378 hospital discharges, costing in excess of


Regenerative Medicine | 2008

Functional recovery in T13–L1 hemisected rats resulting from peripheral nerve rerouting: role of central neuroplasticity

Deniz Konya; Wei Lee Liao; Howard Choi; Dou Yu; Kimberly M. Newton; Allyson M. King; Necmettin Pamir; Peter McL. Black; Walter R. Frontera; Sunil Sabharwal; Yang D. Teng

7.19 million. This approximated a cost of outpatient care received of


Neuroscience | 2008

Neural and anatomical abnormalities of the gastrointestinal system resulting from contusion spinal cord injury.

Serdar Kabatas; Dou Yu; Xue Dao He; Hemant S. Thatte; Darcy Benedict; Kemal Hepgul; Peter McL. Black; Sunil Sabharwal; Yang D. Teng

7.28 million for our entire sample. Conclusions: The comprehensive nature of health care delivery and related cost capture for people with chronic SCI in the VHA provided us the opportunity to accurately determine health care costs for this population. Future SCI postacute care cost analyses should consider case-mix adjusting patients at high risk for rehospitalization.


PLOS ONE | 2016

Manual Wheelchair Skills Training for Community-Dwelling Veterans with Spinal Cord Injury: A Randomized Controlled Trial

R. Lee Kirby; Doug Mitchell; Sunil Sabharwal; Mark McCranie; Audrey Nelson

Respiratory dysfunction after cervical spinal cord injury (SCI) has not been examined experimentally using conscious animals, although clinical SCI most frequently occurs in midcervical segments. Here, we report a C5 hemicontusion SCI model in rats with abnormalities that emulate human post-SCI pathophysiology, including spontaneous recovery processes. Post-C5 SCI rats demonstrated deficits in minute ventilation (Ve) responses to a 7% CO2 challenge that correlated significantly with lesion severities (no injury or 12.5, 25, or 50 mm × 10 g weight drop; New York University impactor; p < 0.001) and ipsilateral motor neuron loss (p = 0.016). Importantly, C5 SCI resulted in at least 4 weeks of respiratory abnormalities that ultimately recovered afterward. Because serotonin is involved in respiration-related neuroplasticity, we investigated the impact of activating 5-HT1A receptors on post-C5 SCI respiratory dysfunction. Treatment with the 5-HT1A agonist 8-hydroxy-2-(di-n-propylmino)tetralin (8-OH DPAT) (250 μg/kg, i.p.) restored hypercapnic Ve at 2 and 4 weeks after injury (i.e., ∼39.2% increase vs post-SCI baseline; p ≤ 0.033). Improvements in hypercapnic Ve response after single administration of 8-OH DPAT were dose dependent and lasted for ∼4 h(p ≤ 0.038 and p ≤ 0.024, respectively). Treatment with another 5-HT1A receptor agonist, buspirone (1.5 mg/kg, i.p.), replicated the results, whereas pretreatment with a 5-HT1A-specific antagonist, 4-iodo-N-[2-[4(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinyl-benzamide (3 mg/kg, i.p.) given 20 min before 8-OH DPAT negated the effect of 8-OH DPAT. These results imply a potential clinical use of 5-HT1A agonists for post-SCI respiratory disorders.


Muscle & Nerve | 2006

Single muscle fiber size and contractility after spinal cord injury in rats

Walter R. Frontera; Howard Choi; Gomathi Krishnan; Lisa S. Krivickas; Sunil Sabharwal; Yang D. Teng

As data elucidating the complexity of spinal cord injury pathophysiology emerge, it is increasingly being recognized that successful repair will probably require a multifaceted approach that combines tactics from various biomedical disciplines, including pharmacology, cell transplantation, gene therapy and material sciences. Recently, new evidence highlighting the benefit of physical activity and rehabilitation interventions during the post-injury phase has provided novel possibilities in realizing effective repair after spinal cord injury. However, before a comprehensive therapeutic strategy that optimally utilizes the benefits of each of these disciplines can be designed, the basic mechanisms by which these various interventions act must be thoroughly explored and important synergistic and antagonistic interactions identified. In examining the mechanisms by which physical activity-based functional recovery after spinal cord injury is effected, endogenous neural stem cells, in our opinion, engender a potentially key role. Multipotent neural stem cells possess many faculties that abet recovery, including the ability to assess the local microenvironment and deliver biofactors that promote neuroplasticity and regeneration, as well as the potential to replenish damaged or eradicated cellular elements. Encouragingly, the functional recovery owing to physical activity-based therapies appears relatively robust, even when therapy is initiated in the chronic stage of spinal cord injury. In this article, we review experimental outcomes related to our hypothesis that endogenous neural stem cells mediate the functional recovery noted in spinal cord injury following physical activity-based treatments. Overall, the data advocates the incorporation of increased physical activity as a component of the multidimensional treatment of spinal cord injury and underscores the critical need to employ research-based mechanistic approaches for developing future advances in the rehabilitation of neurological injury and disorders.


Archives of Physical Medicine and Rehabilitation | 1998

Physiologic comparison of forward and reverse wheelchair propulsion

Frank J. Salvi; Martin D. Hoffman; Sunil Sabharwal; Philip S. Clifford

We investigated the effects of clenbuterol, a beta2-adrenoceptor agonist with known anabolic and neuroprotective properties, on G93A-SOD1 mice, a transgenic murine model of familial amyotrophic lateral sclerosis (ALS). Relative to saline-treated vehicle controls (0.2 ml/kg/day; i.p.), early pathologic G93A-SOD1 mice treated with clenbuterol (1.5 mg/kg/day; i.p.) demonstrated a delayed onset of hindlimb signs as measured by rotarod performance, slowed disease progression, as well as trends toward mitigated losses of lumbar motoneurons and body weight. Responses in female G93A-SOD1 mice were favorable to those of males, suggesting synergistic effects between clenbuterol and sex-specific factors. Overall, our data suggest that clenbuterol offers therapeutic effects on ALS-related neuromuscular degeneration.

Collaboration


Dive into the Sunil Sabharwal's collaboration.

Top Co-Authors

Avatar

Howard Choi

Spaulding Rehabilitation Hospital

View shared research outputs
Top Co-Authors

Avatar

Yang D. Teng

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Deniz Konya

Bahçeşehir University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Peter McL. Black

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge